Genmab AS Valuation
| GMAB Stock | USD 29.44 0.20 0.68% |
At this time, the firm appears to be undervalued. Genmab AS retains a regular Real Value of $34.09 per share. The prevalent price of the firm is $29.44. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Return On Asset of 0.081, current valuation of 16.84 B, and Return On Equity of 0.18 as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 3.729 | Enterprise Value | Enterprise Value Ebitda 11.4086 | Price Sales 4.8437 | Forward PE 14.556 |
Undervalued
Today
Please note that Genmab AS's price fluctuation is very steady at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 29.44 | Real 34.09 | Target 37.39 | Hype 29.47 | Naive 30.1 |
The real value of Genmab Stock, also known as its intrinsic value, is the underlying worth of Genmab AS Company, which is reflected in its stock price. It is based on Genmab AS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Genmab AS Cash |
|
Genmab AS Total Value Analysis
Genmab AS is currently forecasted to have valuation of 16.84 B with market capitalization of 18.02 B, debt of 35.36 B, and cash on hands of 21.61 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Genmab AS fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.84 B | 18.02 B | 35.36 B | 21.61 B |
Genmab AS Investor Information
The book value of the company was currently reported as 94.89. The company has Price/Earnings To Growth (PEG) ratio of 1.08. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018. Based on the key indicators related to Genmab AS's liquidity, profitability, solvency, and operating efficiency, Genmab AS may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Genmab AS Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genmab AS has an asset utilization ratio of 28.99 percent. This suggests that the Company is making $0.29 for each dollar of assets. An increasing asset utilization means that Genmab AS is more efficient with each dollar of assets it utilizes for everyday operations.Genmab AS Profitability Analysis
Based on Genmab AS's profitability indicators, Genmab AS's profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Genmab AS's ability to earn profits and add value for shareholders.Net Income | First Reported 2009-03-31 | Previous Quarter 401 M | Current Value 197 M | Quarterly Volatility 822.6 M |
For Genmab AS profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Genmab AS to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Genmab AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Genmab AS's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Genmab AS over time as well as its relative position and ranking within its peers.
Genmab AS Earnings per Share Projection vs Actual
The next projected EPS of Genmab AS is estimated to be 0.275 with future projections ranging from a low of 0.27 to a high of 0.28. Genmab AS's most recent 12-month trailing earnings per share (EPS TTM) is at 1.54. Please be aware that the consensus of earnings estimates for Genmab AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Genmab AS Earnings Estimation Breakdown
The calculation of Genmab AS's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Genmab AS is estimated to be 0.275 with the future projection ranging from a low of 0.27 to a high of 0.28. Please be aware that this consensus of annual earnings estimates for Genmab AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.27 Lowest | Expected EPS | 0.28 Highest |
Genmab AS Earnings Projection Consensus
Suppose the current estimates of Genmab AS's value are higher than the current market price of the Genmab AS stock. In this case, investors may conclude that Genmab AS is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Genmab AS's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 9 | 55.72% | 0.0 | 0.275 | 1.54 |
Genmab AS Ownership Allocation
Genmab AS has a total of 616.23 Million outstanding shares. Roughly 87.87 (percent) of Genmab AS outstanding shares are held by general public with 0.01 % owned by insiders and only 12.12 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genmab AS Profitability Analysis
The company reported the previous year's revenue of 23.73 B. Net Income was 6.14 B with profit before overhead, payroll, taxes, and interest of 3.48 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genmab AS's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genmab AS and how it compares across the competition.
About Genmab AS Valuation
The stock valuation mechanism determines Genmab AS's current worth on a weekly basis. Our valuation model uses a comparative analysis of Genmab AS. We calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genmab AS's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 21.8 B | 22.8 B | |
| Pretax Profit Margin | 0.32 | 0.31 | |
| Operating Profit Margin | 0.34 | 0.32 | |
| Net Profit Margin | 0.26 | 0.25 | |
| Gross Profit Margin | 0.92 | 0.96 |
Genmab AS Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 626.9 M | |
| Quarterly Earnings Growth Y O Y | -0.944 | |
| Forward Price Earnings | 14.556 |
Genmab AS Current Valuation Indicators
Valuation refers to the process of determining the present value of Genmab AS and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Genmab we look at many different elements of the entity such as Genmab's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Genmab AS, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Genmab AS's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Genmab AS's worth.Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |